La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Stoke Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Stoke Therapeutics..

Stoke Therapeutics (NASDAQ:STOK) Azioni, Catena delle Opzioni

STOKE THERAPEUTICS INC

Stoke Therapeutics

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Stoke Therapeutics Inc

Press Releases

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

News

Health Care

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

BIIB

STOK

Ardelyx

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Biohaven

CureVac

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Immunome

Janux Therapeutics

MiMedx Group

NuCana

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Novavax

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Precigen

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Arcus Biosciences

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Tourmaline Bio

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

Chardan Capital

Wedbush

Jefferies

Needham

HC Wainwright & Co.

Comments

Stoke Therapeutics

Stoke Therapeutics (STOK) Opzioni

Stoke Therapeutics (NASDAQ:STOK) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO